Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash from Financing Activities (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Cash from Financing Activities for 13 consecutive years, with -$80000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 102.13% to -$80000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $6.9 million, a 28.81% increase, with the full-year FY2025 number at $6.9 million, up 28.81% from a year prior.
  • Cash from Financing Activities was -$80000.0 for Q4 2025 at Niagen Bioscience, down from $148000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $33.4 million in Q1 2021 to a low of -$80000.0 in Q4 2025.
  • A 5-year average of $2.8 million and a median of $105500.0 in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 90291.89% in 2021, then plummeted 1300.0% in 2024.
  • Niagen Bioscience's Cash from Financing Activities stood at $63000.0 in 2021, then surged by 12088.89% to $7.7 million in 2022, then plummeted by 100.99% to -$76000.0 in 2023, then soared by 5031.58% to $3.7 million in 2024, then plummeted by 102.13% to -$80000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Cash from Financing Activities are -$80000.0 (Q4 2025), $148000.0 (Q3 2025), and $3.7 million (Q2 2025).